FDA — authorised 23 November 2021
- Application: NDA215596
- Marketing authorisation holder: TAKEDA PHARMS USA
- Status: supplemented
FDA authorised LIVTENCITY on 23 November 2021
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 23 November 2021; FDA has authorised it.
TAKEDA PHARMS USA holds the US marketing authorisation.